Tag Archives: VC

Hot Investor Mandate 1: China-Based VC Firm Can Invest Up to $50M in Life Science Companies, Including Therapeutics, Medical Devices, Diagnostics, and Digital Health

14 Jun

A venture firm based in China with offices in the West and East Coast currently funds healthcare companies out of their $3.5B fund. The firm is interested in companies raising their seed to Series A rounds and provides investments that can range from $5M to $50M depending on the opportunity. The firm seeks opportunities globally, though has a preference on companies based in China.

The firm is interested in therapeutics, medical devices without drug components, in-vitro diagnostics, and healthcare IT. The firm is interested in preclinical to early-stage clinical (Ph I-II) technologies. The firm is indication agnostic, though highly prefers technology with a China market angle.

The firm does not have a management team requirement, and will help support early-stage companies with filling management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , ,

Hot Investor Mandate 2: Taiwan Cross Border VC Seeks Medical Devices, Diagnostic Tools, Digital Health, Healthcare IoT Technologies

7 Jun

An early-stage venture capital firm based in Taipei, Taiwan is actively investing in the life sciences space. Formed by a group of successful entrepreneurs, the firm specializes in incubation, seed and early venture investments in technology-heavy sectors. The firm is currently investing from its $35 million fund that closed in 2016. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firm generally leads a financing round but is also open to syndication. The firm is currently seeking opportunities from Taiwan and the United States.

Within life sciences, the firm considers medical devices, IVD tools, digital health and healthcare internet of things (IoT). Within medtech, the firm is looking for early stage projects with solid unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , ,

Hot Investor Mandate 3: Joint Initiative Launched by a Leading Pharma and VC Firm Invests in Digital Health Companies with USA Focus

7 Jun

A digital health investment company launched in 2016 by a leading pharma and venture capital firm in the industry focuses on the digital health space ranging from therapeutics to diagnostic solutions in areas such as: precision medicine, behavioral health, wearables, and data analytics. The firm is seeking to make 6-8 new investments within the next two years. The firm’s investments range dependent on the opportunity, and focuses on investing in Seed to Series A rounds. For earlier stage companies, the firm has the ability to both lead and co-invest. The firm focuses on companies based in the U.S., but is open to invest globally.

The firm focuses on digital health technologies and solutions that aim to improve patient care and lifestyle. The firm is especially interested in technology with a software component, such as those that control patient care through monitoring medications and therapies, as well as technology with a big data component. The firm will only look at devices if they have an information component and/or generate data. The firm is also interested in technology with machine-learning applications. The firm is not interested in pure EMR or hospital IT systems. Based on all the criteria, the firm is indication agnostic.

The firm is a very active investor that seeks to be fully involved in their portfolio companies. The firm will take a board seat after the investment and will help companies fill management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , ,

Hot Investor Mandate 3: Boston-Based VC Firm Makes Pre-Seed/Seed Investments in Data-Driven Technologies Including AI, Drug Discovery, and Computational Biotech

31 May

A venture firm headquartered in Boston, MA focus on pre-seed and seed stage investments, typically with an initially investment of $500K to $1M as part of the company’s first institutional funding. The firm prefers companies located in the USA and Canada. The firm will make 5-10 new investments over the next 12 months.

The firm partners with entrepreneurs solving real-world problems with data and machine learning, focusing on applications of frontier technologies such as AI, computational biotech, connected sensors, AR/VR, and blockchain. Past investments include biomedical and genomics data analytics platforms, data and analysis tools for drug discovery, and related areas.

The firm desires experienced management teams with a vision for the future. The firm can take a board seat when they have specific expertise in the area, and does not have an equity target. Strong technical teams who have a deep understanding of their markets is desired, though the firm is comfortable partnering with very early-stage (pre-product) companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , ,

Hot Investor Mandate 4: VC Firm with Offices in New England Seeks Digital Health Platform Companies Relating to Drug Discovery, Delivery, and Manufacturing

24 May

A venture capital firm with offices in the New England region currently manages four funds, two of which are dedicated to sector specific investments. The first focuses on healthcare and life science investments, while the other is focused on investing in built environment technology. On average, the initial size of investment is up to $1M, and the firm has the capacity to invest $2-4 M after the initial investment. The firm initially invests from Seed to Series A typically, but has come in at later stage investments. The firm is willing to lead in seed rounds and co-invest in later rounds. The firm has a preference for investing in US, but can invest globally. The firm is actively seeking new investment opportunities.

The firm is a flexible investor that is currently looking for life science platforms relating to drug discovery, delivery, and manufacturing and digital health companies. The firm typically does not invest in therapeutics, medical devices, and diagnostics. The firm prefers enterprise to direct-to-consumer health IT companies. In addition, the firm prefers companies that meet at least $1M revenue traction on the health IT side.

The firm will invest in privately held companies only. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , ,

Hot Investor Mandate 3: California-Based VC Seeking to Invest in Therapeutic Technologies that Solve Problems Within Genetically Driven Diseases

17 May

A California-based firm backed by a number of well-known global funds is actively seeking investment opportunities. The firm prefers to be the first institutional investor in a company, and is typically an active, lead investor (often the sole investor). The firm typically invests in 5 opportunities per year.

The firm focuses on genetic drivers of disease, and therefore only invests in treatments for monogenic diseases or genetically-driven cancers. The firm is only interested in treatments that elicit a disease-modifying response; treatments that target symptoms of monogenic diseases are not of interest. Therapeutics must have a clearly-defined mechanism of action. The firm usually invests at the preclinical stage, up to 18 months prior to IND, but is open to later stage candidates (including clinical).

The firm focuses on individual products, not technology platforms. The firm typically houses each single asset in its own discrete subsidiary. The firm has internal expertise in medicinal chemistry, biology, and clinical trials, with personnel having significantly contributed to 30+ INDs and 10+ approved drugs. The company will often leverage internal expertise for subsidiaries, and can also assist with recruiting.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 4: Chinese VC/PE Firm Works on Early and Late-Stage Deals in Medical Devices and Therapeutics with China Market Potential

17 May

A Shanghai-based venture capital/private equity firm manages both USD and RMB denominated funds. The firm invests in Series A rounds at $1-2M, though its sweet spot is investing $10-15M in Series B/C rounds. The firm works closely with local provincial Chinese governments, allowing them the ability to bring technology successfully into the Chinese market. The firm will generally not invest in the seed stage and seeks opportunities globally.

The firm invests in pharmaceuticals and Class II medical devices, including an interest in 505(b)(2) repurposed compounds, as well as healthcare-related industries. The firm is interested in all therapeutic areas and in early to mid-development stage companies. The firm focuses on unmet medical needs with a China market potential.

The firm does not have management team requirements. The firm will typically take a board seat post-investment, and has the capability to lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , ,

← Older Entries
Newer Entries →